Follow
Roberto Carmagnani Pestana
Roberto Carmagnani Pestana
Verified email at einstein.br
Title
Cited by
Cited by
Year
Antibody–drug conjugates: Smart chemotherapy delivery across tumor histologies
P Tarantino, R Carmagnani Pestana, C Corti, S Modi, A Bardia, ...
CA: a cancer journal for clinicians 72 (2), 165-182, 2022
1862022
IL-6–mediated induction of matrix metalloproteinase-9 is modulated by JAK-dependent IL-10 expression in macrophages
P Kothari, R Pestana, R Mesraoua, R Elchaki, KM Khan, AJ Dannenberg, ...
The Journal of Immunology 192 (1), 349-357, 2014
1542014
Hepatocellular carcinoma immunotherapy
RC Sperandio, RC Pestana, BV Miyamura, AO Kaseb
Annual review of medicine 73, 267-278, 2022
1072022
Histology-agnostic drug development—considering issues beyond the tissue
RC Pestana, S Sen, BP Hobbs, DS Hong
Nature Reviews Clinical Oncology 17 (9), 555-568, 2020
802020
Molecular profiling of hepatocellular carcinoma using circulating cell-free DNA
AO Kaseb, NS Sánchez, S Sen, RK Kelley, B Tan, AG Bocobo, KH Lim, ...
Clinical Cancer Research 25 (20), 6107-6118, 2019
692019
Immunologic correlates of pathologic complete response to preoperative immunotherapy in hepatocellular carcinoma
AO Kaseb, L Vence, J Blando, SS Yadav, N Ikoma, RC Pestana, ...
Cancer immunology research 7 (9), 1390-1395, 2019
66*2019
Prognostic factors in patients with metastatic breast cancer with bone‐only metastases
A Parkes, CL Warneke, K Clifton, A Al‐Awadhi, O Oke, RC Pestana, ...
The oncologist 23 (11), 1282-1288, 2018
562018
Impact of antibiotic use on survival in patients with advanced cancers treated on immune checkpoint inhibitor phase I clinical trials
S Sen, RC Pestana, K Hess, GM Viola, V Subbiah
Annals of Oncology 29 (12), 2396-2398, 2018
542018
Randomized, open-label, perioperative phase II study evaluating nivolumab alone versus nivolumab plus ipilimumab in patients with resectable HCC
A Kaseb, DG Duda, HST Cao, YI Abugabal, LM Vence, A Rashid, ...
Annals of Oncology 30, v880, 2019
532019
Moving beyond 3+ 3: the future of clinical trial design
R Kurzrock, CC Lin, TC Wu, BP Hobbs, RC Pestana, DS Hong
American Society of Clinical Oncology Educational Book 41, e133-e144, 2021
492021
Response rates and survival to systemic therapy after immune checkpoint inhibitor failure in recurrent/metastatic head and neck squamous cell carcinoma
RC Pestana, M Becnel, ML Rubin, DK Torman, J Crespo, J Phan, ...
Oral Oncology 101, 104523, 2020
472020
Immunotherapy response evaluation with magnetic resonance elastography (MRE) in advanced HCC
A Qayyum, KP Hwang, J Stafford, A Verma, DM Maru, S Sandesh, J Sun, ...
Journal for immunotherapy of cancer 7, 1-6, 2019
422019
Origin and role of hepatic myofibroblasts in hepatocellular carcinoma
BG Yavuz, RC Pestana, YI Abugabal, S Krishnan, J Chen, MM Hassan, ...
Oncotarget 11 (13), 1186, 2020
382020
Precision oncology in sarcomas: divide and conquer
R Carmagnani Pestana, R Groisberg, J Roszik, V Subbiah
JCO Precision Oncology 3, 1-16, 2019
312019
Systemic options for malignant peripheral nerve sheath tumors
A Hassan, RC Pestana, A Parkes
Current treatment options in oncology 22 (4), 33, 2021
252021
Unique aberrations in intimal sarcoma identified by next-generation sequencing as potential therapy targets
J Roszik, A Khan, AP Conley, JA Livingston, R Groisberg, V Ravi, ...
Cancers 11 (9), 1283, 2019
222019
Consequences of the implementation of the Model for End-stage Liver Disease system for liver allocation in Brazil
RC Pestana, EI Baracat, PCB Massarollo, LA Pereira, LA Szutan
Transplantation proceedings 45 (6), 2111-2114, 2013
222013
Clinical and prognostic significance of circulating levels of angiopoietin-1 and angiopoietin-2 in hepatocellular carcinoma
RC Pestana, MM Hassan, R Abdel-Wahab, YI Abugabal, LM Girard, D Li, ...
Oncotarget 9 (102), 37721, 2018
202018
Impact of tissue-agnostic approvals for patients with sarcoma
RC Pestana, JR Beal, A Parkes, N Hamerschlak, V Subbiah
Trends in Cancer 8 (2), 135-144, 2022
152022
Precision medicine targeting FGFR2 genomic alterations in advanced cholangiocarcinoma: current state and future perspectives
M Zugman, G Botrus, RC Pestana, PLS Uson Junior
Frontiers in Oncology 12, 860453, 2022
132022
The system can't perform the operation now. Try again later.
Articles 1–20